Eton Pharma Q4 2024 revenue $11.6M (+59% YoY); net loss narrows to $0.6M

Eton Pharmaceuticals, Inc.

Record product revenue of $11.6M in Q4 2024, up 59% from Q4 2023; 16th consecutive quarter of sequential growth.
Net loss improved to $0.6M ($0.02/share) vs $2.3M loss ($0.09/share) in Q4 2023.
Closed transformational acquisition of Increlex (relaunched Jan 2025) and acquired Galzin; both tracking ahead of expectations.
Positive pivotal study for ET-600; NDA submission planned April 2025; ET-400 launch inventory ready with PDUFA May 28.
Cash balance $14.9M at Dec 31, 2024; company expects sequential revenue growth to continue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.